<p>隨着歐洲市場在地緣政治緊張局勢和波動的能源價格驅動下應對不確定性，泛歐 STOXX 歐洲 600 指數顯示出適度的漲幅，反映出投資者的謹慎樂觀。在這種環境下，內部持股比例高的成長型公司尤其吸引人，因為它們通常表現出管理層與股東利益之間的強烈一致性，可能在市場波動中提供韌性。</p>
<h3>歐洲內部持股比例高的十大成長型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>MilDef Group (OM:MILDEF)</td>
<td>13.7%</td>
<td>34.7%</td>
</tr>
<tr>
<td>MedinCell (ENXTPA:MEDCL)</td>
<td>11.5%</td>
<td>117.6%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>35%</td>
<td>80.1%</td>
</tr>
<tr>
<td>Induct (OB:INDCT)</td>
<td>10.5%</td>
<td>98.6%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>21.6%</td>
<td>124.9%</td>
</tr>
<tr>
<td>CTT Systems (OM:CTT)</td>
<td>17.4%</td>
<td>42.7%</td>
</tr>
<tr>
<td>Clavister Holding AB (publ.) (OM:CLAV)</td>
<td>18%</td>
<td>116.2%</td>
</tr>
<tr>
<td>Circus (XTRA:CA1)</td>
<td>21.9%</td>
<td>88.1%</td>
</tr>
<tr>
<td>Bonesupport Holding (OM:BONEX)</td>
<td>10.2%</td>
<td>34%</td>
</tr>
<tr>
<td>Bergen Carbon Solutions (OB:BCS)</td>
<td>10.2%</td>
<td>55.5%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們快速成長的歐洲內部持股比例高的 221 只股票的完整列表。</p>
<p>讓我們深入探討一些篩選出的優質選擇。</p>
<h2>P/F Bakkafrost (OB:BAKKA)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> P/F Bakkafrost 及其子公司在北美、西歐、東歐、亞洲及其他國際市場從事三文魚產品的生產和銷售；其市值為 268.5 億挪威克朗。</p>
<p><strong>運營：</strong> 公司的收入細分包括銷售及其他收入為 102.8 億丹麥克朗，法羅羣島養殖為 40.5 億丹麥克朗，魚粉、油和飼料為 26 億丹麥克朗，服務為 9.2052 億丹麥克朗，蘇格蘭養殖為 11.2 億丹麥克朗，法羅羣島淡水養殖為 8.9677 億丹麥克朗，蘇格蘭淡水養殖為 1.6946 億丹麥克朗。</p>
<p><strong>內部持股比例：</strong> 23.7%</p>
<p><strong>收益增長預測：</strong> 每年 36%。</p>
<p>P/F Bakkafrost 是一家內部持股比例高的歐洲成長型公司，預計年收益增長將達到 36%，超過挪威市場。儘管其交易價格大幅低於估計的公允價值，但公司的收入增長預計為每年 12.6%。最近對其章程的修訂允許回購最多 10% 的總資本。然而，最近的收益顯示年淨收入有所下降，儘管季度有所改善。</p>
<ul>
<li>點擊這裏發現 P/F Bakkafrost 的細微差別，查看我們的詳細分析未來增長報告。</li>
<li>我們最近的估值報告指出 P/F Bakkafrost 的股票在市場上可能被低估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/46d88a0e-736c-49a8-b85c-575da11fb6fe/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/46d88a0e-736c-49a8-b85c-575da11fb6fe/chart/earnings-and-revenue-growth"/></p>
<p>OB:BAKKA 收益和收入增長截至 2026 年 4 月</p>
<h2>Sdiptech (OM:SDIP B)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Sdiptech AB（上市公司）在多個國家（包括瑞典、英國和美國）提供基礎設施的技術服務，市值為 76.3 億瑞典克朗。</p>
<p><strong>運營：</strong> 公司的收入細分包括安全與安保（4.3 億瑞典克朗）、水與生物經濟（9.13 億瑞典克朗）、能源與電氣化（10.7 億瑞典克朗）和供應鏈與運輸（20.8 億瑞典克朗）。</p>
<p><strong>內部持股比例：</strong> 11.6%</p>
<p><strong>收益增長預測：</strong> 每年 51.6%。</p>
<p>Sdiptech 內部持股比例高，預計年收益將增長 51.59%，並在三年內實現盈利，超過市場平均增長。儘管交易價格低於估計的公允價值 54.2%，分析師預計價格將上漲 35.1%，但公司面臨高債務水平。最近的活動包括以 1.84 億瑞典克朗贖回優先股和以溢價回購價值 2.5 億瑞典克朗的債券，表明在其增長軌跡中進行戰略財務重組的努力。</p>
<ul>
<li>點擊這裏深入瞭解 Sdiptech 的完整分析未來增長報告。</li>
<li>我們的估值報告揭示了 Sdiptech 的股票可能在折扣交易。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/087f171a-1bc7-42f1-8527-d29f5f936469/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/087f171a-1bc7-42f1-8527-d29f5f936469/chart/earnings-and-revenue-growth"/></p>
<p>OM:SDIP B 收益和收入增長截至 2026 年 4 月</p>
<h2>Redcare Pharmacy (XTRA:RDC)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Redcare Pharmacy NV 在多個歐洲國家（包括荷蘭、德國、意大利、比利時、瑞士、奧地利和法國）經營在線藥房業務，市值為 7.4895 億歐元。</p>
<p><strong>運營：</strong> 公司的收入分為來自 DACH 地區的 24 億歐元和國際市場的 5.4 億歐元。</p>
<p><strong>內部持股比例：</strong> 13.7%</p>
<p><strong>收益增長預測：</strong> 每年 53.5%。</p>
<p>Redcare Pharmacy 內部持股比例高，預計在三年內實現盈利並超過市場平均增長。儘管交易價格低於其估計公允價值 79.8%，但面臨高股價波動和 2025 年 3700 萬歐元的淨虧損等挑戰。預計 2026 年收入將增長 13-15%，受益於數字醫療創新，如德國遠程醫療基礎設施現代化中的電子處方 PoPP 模塊。</p>
<ul>
<li>點擊這裏深入瞭解 Redcare Pharmacy 的具體情況，查看我們的詳細增長預測報告。</li>
<li>根據我們的估值報告，Redcare Pharmacy 的股價可能處於較低水平。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bd9541e9-75b0-454c-8046-a7084a97c9e9/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bd9541e9-75b0-454c-8046-a7084a97c9e9/chart/ownership-breakdown"/></p>
<p>XTRA:RDC 股權結構截至 2026 年 4 月</p>
<h2>利用機會</h2>
<ul>
<li>點擊此鏈接深入瞭解我們快速成長的歐洲內部持股比例高的 221 家公司。</li>
<li>準備好不同的方式了嗎？尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和盈利增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
<h3><strong>新功能：</strong> 在一個地方管理您的所有股票投資組合</h3>
<p>我們為股票投資者創建了 <strong>終極投資組合伴侶</strong>，<strong>而且是免費的。</strong></p>
<p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
<p>• 通過電子郵件或手機接收新的警告信號或風險提示</p>
<p>• 跟蹤您股票的公允價值</p>
<p>免費試用演示投資組合</p>

BAKK

<p>本文討論了三家歐洲成長型公司，它們的內部持股比例較高：P/F Bakkafrost、Sdiptech 和 Redcare Pharmacy。P/F Bakkafrost 的內部持股比例為 23.7%，預計年收益增長將達到 36%，儘管最近淨收入有所下降。Sdiptech 的內部持股比例為 11.6%，預計年收益增長為 51.6%，但面臨高債務水平。Redcare Pharmacy 的內部持股比例為 13.7%，預計年收益增長為 53.5%，同時其交易價格顯著低於估算的公允價值。文章強調了這些公司在市場波動中潛在的韌性</p>

<p>As the European markets navigate through uncertainty driven by geopolitical tensions and fluctuating energy prices, the pan-European STOXX Europe 600 Index has shown modest gains, reflecting cautious optimism among investors. In this environment, growth companies with high insider ownership can be particularly appealing as they often demonstrate strong alignment between management and shareholder interests, potentially offering resilience amid market volatility.</p>
<div class="lb-trans"><p>隨着歐洲市場在地緣政治緊張局勢和波動的能源價格驅動下應對不確定性，泛歐 STOXX 歐洲 600 指數顯示出適度的漲幅，反映出投資者的謹慎樂觀。在這種環境下，內部持股比例高的成長型公司尤其吸引人，因為它們通常表現出管理層與股東利益之間的強烈一致性，可能在市場波動中提供韌性。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In Europe</h3>
<div class="lb-trans"><h3>歐洲內部持股比例高的十大成長型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>MilDef Group (OM:MILDEF)</td>
<td>13.7%</td>
<td>34.7%</td>
</tr>
<tr>
<td>MedinCell (ENXTPA:MEDCL)</td>
<td>11.5%</td>
<td>117.6%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>35%</td>
<td>80.1%</td>
</tr>
<tr>
<td>Induct (OB:INDCT)</td>
<td>10.5%</td>
<td>98.6%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>21.6%</td>
<td>124.9%</td>
</tr>
<tr>
<td>CTT Systems (OM:CTT)</td>
<td>17.4%</td>
<td>42.7%</td>
</tr>
<tr>
<td>Clavister Holding AB (publ.) (OM:CLAV)</td>
<td>18%</td>
<td>116.2%</td>
</tr>
<tr>
<td>Circus (XTRA:CA1)</td>
<td>21.9%</td>
<td>88.1%</td>
</tr>
<tr>
<td>Bonesupport Holding (OM:BONEX)</td>
<td>10.2%</td>
<td>34%</td>
</tr>
<tr>
<td>Bergen Carbon Solutions (OB:BCS)</td>
<td>10.2%</td>
<td>55.5%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>MilDef Group (OM:MILDEF)</td>
<td>13.7%</td>
<td>34.7%</td>
</tr>
<tr>
<td>MedinCell (ENXTPA:MEDCL)</td>
<td>11.5%</td>
<td>117.6%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>35%</td>
<td>80.1%</td>
</tr>
<tr>
<td>Induct (OB:INDCT)</td>
<td>10.5%</td>
<td>98.6%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>21.6%</td>
<td>124.9%</td>
</tr>
<tr>
<td>CTT Systems (OM:CTT)</td>
<td>17.4%</td>
<td>42.7%</td>
</tr>
<tr>
<td>Clavister Holding AB (publ.) (OM:CLAV)</td>
<td>18%</td>
<td>116.2%</td>
</tr>
<tr>
<td>Circus (XTRA:CA1)</td>
<td>21.9%</td>
<td>88.1%</td>
</tr>
<tr>
<td>Bonesupport Holding (OM:BONEX)</td>
<td>10.2%</td>
<td>34%</td>
</tr>
<tr>
<td>Bergen Carbon Solutions (OB:BCS)</td>
<td>10.2%</td>
<td>55.5%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 221 stocks from our Fast Growing European Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們快速成長的歐洲內部持股比例高的 221 只股票的完整列表。</p>
</div><p>Let's dive into some prime choices out of the screener.</p>
<div class="lb-trans"><p>讓我們深入探討一些篩選出的優質選擇。</p>
</div><h2>P/F Bakkafrost (OB:BAKKA)</h2>
<div class="lb-trans"><h2>P/F Bakkafrost (OB:BAKKA)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> P/F Bakkafrost, along with its subsidiaries, is involved in the production and sale of salmon products across North America, Western Europe, Eastern Europe, Asia, and other international markets; it has a market cap of NOK26.85 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> P/F Bakkafrost 及其子公司在北美、西歐、東歐、亞洲及其他國際市場從事三文魚產品的生產和銷售；其市值為 268.5 億挪威克朗。</p>
</div><p><strong>Operations:</strong> The company's revenue segments include Sales and Other at DKK10.28 billion, Farming Faroe Islands at DKK4.05 billion, Fishmeal, Oil and Feed at DKK2.60 billion, Services at DKK920.52 million, Farming Scotland at DKK1.12 billion, Freshwater Faroe Islands at DKK896.77 million, and Freshwater Scotland at DKK169.46 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入細分包括銷售及其他收入為 102.8 億丹麥克朗，法羅羣島養殖為 40.5 億丹麥克朗，魚粉、油和飼料為 26 億丹麥克朗，服務為 9.2052 億丹麥克朗，蘇格蘭養殖為 11.2 億丹麥克朗，法羅羣島淡水養殖為 8.9677 億丹麥克朗，蘇格蘭淡水養殖為 1.6946 億丹麥克朗。</p>
</div><p><strong>Insider Ownership:</strong> 23.7%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 23.7%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 36% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 36%。</p>
</div><p>P/F Bakkafrost, a European growth company with significant insider ownership, is forecast to achieve substantial earnings growth of 36% annually, outpacing the Norwegian market. Despite trading at a considerable discount to its estimated fair value, the company's revenue growth is projected at 12.6% per year. Recent amendments in its Articles of Association allow share buybacks up to 10% of total capital. However, recent earnings showed a decline in annual net income despite quarterly improvements.</p>
<div class="lb-trans"><p>P/F Bakkafrost 是一家內部持股比例高的歐洲成長型公司，預計年收益增長將達到 36%，超過挪威市場。儘管其交易價格大幅低於估計的公允價值，但公司的收入增長預計為每年 12.6%。最近對其章程的修訂允許回購最多 10% 的總資本。然而，最近的收益顯示年淨收入有所下降，儘管季度有所改善。</p>
</div><ul>
<li>Click here to discover the nuances of P/F Bakkafrost with our detailed analytical future growth report.</li>
<li>Insights from our recent valuation report point to the potential undervaluation of P/F Bakkafrost shares in the market.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏發現 P/F Bakkafrost 的細微差別，查看我們的詳細分析未來增長報告。</li>
<li>我們最近的估值報告指出 P/F Bakkafrost 的股票在市場上可能被低估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/46d88a0e-736c-49a8-b85c-575da11fb6fe/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/46d88a0e-736c-49a8-b85c-575da11fb6fe/chart/earnings-and-revenue-growth"/></p>
<p>OB:BAKKA Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>OB:BAKKA 收益和收入增長截至 2026 年 4 月</p>
</div><h2>Sdiptech (OM:SDIP B)</h2>
<div class="lb-trans"><h2>Sdiptech (OM:SDIP B)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Sdiptech AB (publ) offers technical services for infrastructures across several countries including Sweden, the United Kingdom, and the United States, with a market cap of SEK7.63 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Sdiptech AB（上市公司）在多個國家（包括瑞典、英國和美國）提供基礎設施的技術服務，市值為 76.3 億瑞典克朗。</p>
</div><p><strong>Operations:</strong> The company's revenue segments include Safety &amp; Security (SEK430 million), Water &amp; Bioeconomy (SEK913 million), Energy &amp; Electrification (SEK1.07 billion), and Supply Chain &amp; Transportation (SEK2.08 billion).</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入細分包括安全與安保（4.3 億瑞典克朗）、水與生物經濟（9.13 億瑞典克朗）、能源與電氣化（10.7 億瑞典克朗）和供應鏈與運輸（20.8 億瑞典克朗）。</p>
</div><p><strong>Insider Ownership:</strong> 11.6%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 11.6%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 51.6% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 51.6%。</p>
</div><p>Sdiptech, with strong insider ownership, is expected to grow earnings by 51.59% annually and become profitable within three years, surpassing average market growth. Although trading 54.2% below estimated fair value and analysts anticipate a 35.1% price increase, the company faces high debt levels. Recent activities include redeeming preference shares for SEK 184 million and repurchasing bonds worth SEK 250 million at a premium, indicating strategic financial restructuring efforts amidst its growth trajectory.</p>
<div class="lb-trans"><p>Sdiptech 內部持股比例高，預計年收益將增長 51.59%，並在三年內實現盈利，超過市場平均增長。儘管交易價格低於估計的公允價值 54.2%，分析師預計價格將上漲 35.1%，但公司面臨高債務水平。最近的活動包括以 1.84 億瑞典克朗贖回優先股和以溢價回購價值 2.5 億瑞典克朗的債券，表明在其增長軌跡中進行戰略財務重組的努力。</p>
</div><ul>
<li>Delve into the full analysis future growth report here for a deeper understanding of Sdiptech.</li>
<li>Our valuation report unveils the possibility Sdiptech's shares may be trading at a discount.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 Sdiptech 的完整分析未來增長報告。</li>
<li>我們的估值報告揭示了 Sdiptech 的股票可能在折扣交易。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/087f171a-1bc7-42f1-8527-d29f5f936469/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/087f171a-1bc7-42f1-8527-d29f5f936469/chart/earnings-and-revenue-growth"/></p>
<p>OM:SDIP B Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>OM:SDIP B 收益和收入增長截至 2026 年 4 月</p>
</div><h2>Redcare Pharmacy (XTRA:RDC)</h2>
<div class="lb-trans"><h2>Redcare Pharmacy (XTRA:RDC)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Redcare Pharmacy NV operates an online pharmacy business across several European countries including the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France with a market cap of €748.95 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Redcare Pharmacy NV 在多個歐洲國家（包括荷蘭、德國、意大利、比利時、瑞士、奧地利和法國）經營在線藥房業務，市值為 7.4895 億歐元。</p>
</div><p><strong>Operations:</strong> The company's revenue is segmented into €2.40 billion from the DACH region and €540 million internationally.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入分為來自 DACH 地區的 24 億歐元和國際市場的 5.4 億歐元。</p>
</div><p><strong>Insider Ownership:</strong> 13.7%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 13.7%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 53.5% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 53.5%。</p>
</div><p>Redcare Pharmacy, with significant insider ownership, is forecast to achieve profitability within three years and surpass average market growth. Despite trading at 79.8% below its estimated fair value, it faces challenges like high share price volatility and a net loss of €37.7 million in 2025. Revenue is expected to grow between 13-15% in 2026, driven by digital healthcare innovations such as the PoPP module for e-prescriptions in Germany's telematics infrastructure modernization.</p>
<div class="lb-trans"><p>Redcare Pharmacy 內部持股比例高，預計在三年內實現盈利並超過市場平均增長。儘管交易價格低於其估計公允價值 79.8%，但面臨高股價波動和 2025 年 3700 萬歐元的淨虧損等挑戰。預計 2026 年收入將增長 13-15%，受益於數字醫療創新，如德國遠程醫療基礎設施現代化中的電子處方 PoPP 模塊。</p>
</div><ul>
<li>Dive into the specifics of Redcare Pharmacy here with our thorough growth forecast report.</li>
<li>According our valuation report, there's an indication that Redcare Pharmacy's share price might be on the cheaper side.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 Redcare Pharmacy 的具體情況，查看我們的詳細增長預測報告。</li>
<li>根據我們的估值報告，Redcare Pharmacy 的股價可能處於較低水平。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bd9541e9-75b0-454c-8046-a7084a97c9e9/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/bd9541e9-75b0-454c-8046-a7084a97c9e9/chart/ownership-breakdown"/></p>
<p>XTRA:RDC Ownership Breakdown as at Apr 2026</p>
<div class="lb-trans"><p>XTRA:RDC 股權結構截至 2026 年 4 月</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用機會</h2>
</div><ul>
<li>Click this link to deep-dive into the 221 companies within our Fast Growing European Companies With High Insider Ownership screener.</li>
<li>Ready For A Different Approach? Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊此鏈接深入瞭解我們快速成長的歐洲內部持股比例高的 221 家公司。</li>
<li>準備好不同的方式了嗎？尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和盈利增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> 在一個地方管理您的所有股票投資組合</h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我們為股票投資者創建了 <strong>終極投資組合伴侶</strong>，<strong>而且是免費的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通過電子郵件或手機接收新的警告信號或風險提示</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟蹤您股票的公允價值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免費試用演示投資組合</p>
</div>

三家歐洲成長型公司擁有高內部持股